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Abstract
Monotherapy with boosted protease inhibitors has emerged as an antiretroviral therapy simplification alternative
for selected patients, endorsed by the results of some randomized clinical trials. However, there are some
concerns about the efficacy of such a strategy in achieving successful viral suppression in those anatomic
compartments or reservoirs in which antiretroviral drug penetration is lower, such as the central nervous system
(CNS). Several studies have demonstrated better neurocognitive performance in patients receiving antiretroviral
drugs with better cerebrospinal fluid (CSF) penetration. Nevertheless, cases of CSF viral escape accompanied
by moderate or severe neurological symptoms have been reported with both standard triple therapy and boosted
protease inhibitor (PI) monotherapy, and it is not well established whether ritonavir-boosted protease inhibitor
(PI/r) monotherapy is associated with a higher risk of symptomatic CSF viral escape or not. Herein, we present
a case of viral rebound and resistance emergence exclusively in CSF associated with an unusual clinical
manifestation of focal encephalitis in a patient with plasma HIV-1 RNA suppression while receiving lopinavir/
ritonavir monotherapy. Clinical resolution and CSF viral suppression were observed after switching to a
genotype-guided combined antiretroviral regimen with good CSF penetration.
Introduction
The use of potent combined antiretroviral ther-apy (cART) has led to a decreased incidence of HIV-
related neurological diseases, including HIV-associated
dementia and central nervous system (CNS) opportunistic
infections and lymphoma.1 Nevertheless, mild or moderate
HIV-associated neurocognitive disorders (HAND) remain
common among HIV-infected patients receiving ART, de-
spite virological suppression and immune recovery.2–4 One
of the mechanisms that could explain HAND is the presence
of subtherapeutic antiretroviral drug levels in cerebrospinal
fluid (CSF), due to the poor penetration of some drugs across
the blood–brain barrier, which allows some degree of viral
replication.5 In line with this, some studies have demonstrated
better neurocognitive performance in patients receiving anti-
retroviral drugs with better CSF penetration.6,7 In addition,
insufficient CSF drug concentrations can cause resistance
emergence and viral escape in CSF while plasma viral sup-
pression persists.8 Although this phenomenon is uncommon, it
has been associated with a variety of neurological disorders,
including acute encephalitis and subacute motor, sensory, and
cognitive disorders.9–11
Ritonavir-boosted protease inhibitor (PI/r) monotherapy
with lopinavir/r or darunavir/r is a treatment simplification
strategy that may reduce drug-related toxicity while main-
taining viral suppression in selected patients.12–15 Despite
the poor blood–brain barrier penetration of lopinavir/r and
darunavir/r, CSF concentrations of both drugs seem sufficient
to exceed the IC50 of a wild-type virus.
16,17 Cases of symp-
tomatic CSF viral escape have been reported with both stan-
dard triple therapy and PI/r monotherapy,9–11,18,19 and it is
uncertain whether PI/rmonotherapy is associatedwith a higher
risk of symptomatic CSF viral escape.20
We present a case of focal encephalitis due to CSF viral
escape associated with resistance emergence exclusively in
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CSF in a patient on lopinavir/ritonavir (LPV/r) monotherapy
with virologic suppression in plasma.
Case Report
We report the case of a 44-year-old woman diagnosed with
HIV-1 infection in 1992. She started ART in 1996 after being
diagnosed with Pneumocystis jiroveci pneumonia. Her CD4 +
T cell count nadir was 58 cells/ll (12%) and her highest
plasma viral load (HIV-1 RNA) before ART was 22,700
copies/ml. She received stavudine, lamivudine, and ritonavir
followed by stavudine, lamivudine, and nelfinavir between
1996 and 2000 with persistent virological failure, but geno-
typic resistance testing was not available.
In 2000, salvage therapy with stavudine, lamivudine, and
lopinavir/r was initiated, achieving a plasma viral load under
the limit of detection. Since then, her plasma viral load has
remained undetectable. ART was switched to tenofovir, la-
mivudine, and lopinavir/r in 2006 and tenofovir/emtricitabine
plus lopinavir/r in 2008. In 2011, therapy was simplified to
lopinavir/r monotherapy. Treatment adherence and tolerance
were good. In the last control, 2 months before hospital ad-
mission and 7 months after switching to monotherapy, her
CD4+ cell count was 810 cells/ll (45%) and her plasmaHIV-1
RNAwas below the limit of detection (less than 40 copies/ml).
In addition, the patient had chronic hepatitis C virus coinfec-
tion with mild to moderate liver fibrosis and depression, which
was currently stable on citalopram treatment.
The patient was admitted to the hospital with a 5-day
history of clonic movements associated with paresthesia in
the left upper and lower limbs and ultimately generalized
seizures, followed by paralysis of the left limbs. At arrival she
had a well-preserved general status, was apyretic, and was
conscious and oriented. The general physical examination
was normal, but the neurological examination showed left
brachiocrural paresis (4/5). During the first 48 h of hospital-
ization, clonic movements in the left limbs persisted. With
the diagnosis of partial status epilepticus, levetiracetam
1,500mg bid + oxcarbazepine 600mg tid were prescribed,
achieving remission. In addition, the patient presented with
fever (37.7–38C), progression of left brachiocrural paresis
(upper limb 2/5, lower limb 1/5), and left perioral paresthesia.
Laboratory tests showed a CD4 count of 576 cells/ll (48%), a
CD4/CD8 ratio of 2.6, plasma HIV-1 RNA of 216 copies/ml
(poor compliance with ART during the past days because of
neurological symptoms), and polyclonal hypergammaglo-
bulinemia. All other hematological and biochemical param-
eters were normal.
A cranial computed tomography (CT) study showed no
abnormalities. However, magnetic resonance imaging (MRI)
of the brain depicted a large area of confluent signal change,
mainly affecting the subcortical white matter of the right
parietal region, with no mass effect. The lesion was hyperin-
tense on T2, FLAIR, and isotropic diffusion-weighted images,
and hypointense on T1-weighted images. The lesion and ad-
jacent perivascular areas showed a slight enhancement fol-
lowing gadolinium injection (Fig. 1a). Dynamic perfusion and
spectroscopic findings were not suggestive of a brain tumor.
At the third day of admission, a lumbar puncture was
performed. CSF findings included leukocytes 130/ll, 99%
lymphocytes, proteins 0.71 g/liter (normal range 0.15–0.45),
and normal glucose levels. Based on the fever and CSF data,
empirical treatment with acyclovir and ampicillin IV was
started. Blood cultures were negative. CSF microbiological
testing was negative [bacterial culture, cryptococcal antigen,
polymerase chain reaction (PCR) for Toxoplasma gondii,
herpes simplex virus, cytomegalovirus, JC virus, and Myco-
bacterium tuberculosis complex] with the exception of PCR
for Epstein–Barr virus (EBV; 1,304 copies/ml) and HIV-1
RNA 24,016 copies/ml. Genotypic resistance testing (GRT)
of HIV-1 RNA from CSF showed several drug resistance-
associated mutations in both the reverse transcriptase (T69N,
V108I, M184V) and protease (V32I, L33F, I54V, L63P,
A71V, V82A, L90M). A neoplastic origin of the brain lesion
was ruled out by cytology and flow cytometry, and a diag-
nosis of HIV-1 encephalitis was established. Antiviral and
antibacterial treatments were withdrawn, and ART was
modified to active antiretroviral drugs according to the GRT
findings, with good penetration through the blood–brain
barrier: abacavir/lamivudine, ritonavir-boosted darunavir,
and raltegravir (2010 CPE score: 10).21
The lopinavir unbound concentration in CSF, determined
by liquid chromatography–tandem mass spectrometry (LC-
MS/MS) in a sample collected 3 days after hospital admission
(6 h after drug intake), was 29 ng/ml (lopinavir CE50 for wild-
type virus, 1.9 ng/ml).16 Due to the low plasma HIV-1 RNA
FIG. 1. (a) T2-weighted magnetic
resonance (MR) images at hospital
admission: large hyperintense area
mainly affecting the subcortical
white matter of the right parietal
region, with no mass effect. (b) T2-
weighted MR images 3 months after
the diagnosis and change of anti-
retroviral therapy: reduction of the
size and hyperintensity of the lesion.
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level, GRT was not performed on the plasma sample. To
determine whether HIV-1 replication and resistance selection
were restricted to the CSF, GRT was carried out in proviral
DNA from peripheral blood mononuclear cells and no re-
sistance-associated mutations were found.
The patient’s clinical evolution was favorable. Eleven days
after the change in ART the CSF characteristics were normal
and CSF HIV-1 RNA was undetectable. The patient did not
present new seizures, and left brachiocrural paresis improved
except for a minimal residual motor impairment of the left
foot. MRI performed 3 months later showed a decrease in the
size of the frontoparietal lesion and contrast enhancement
(Fig. 1b).
Discussion
We report a well-documented case of focal encephalitis
related to viral escape and resistance emergence in the CSF of
a patient with plasma HIV-1 RNA suppression on lopinavir/
ritonavir monotherapy.
It is noteworthy that EBV activitywas also observed inCSF.
Although a wide spectrum of EBV-associated neurological
diseases has been reported, neurological symptoms are rarely
present in the absence of EBV systemic infection and CSF
EBV activity occurs more frequently as intrathecal EBV re-
activation in association with lymphoma or other CNS infec-
tions rather than as the primary cause of a CNS infection.22 In
our patient, plasma anti-EBV IgG antibodies had been tested
in 2006 and they were positive. In addition, EBV viral load in
CSF was not high, primary CNS lymphoma was ruled out, and
neurological manifestations improved after optimization of
ART. Therefore, EBV activity in CSF could be interpreted as a
reactivation in the setting of HIV escape-related encephalitis.
The efficacy and safety of monotherapy with ritonavir-
boosted lopinavir or darunavir have been assessed in clinical
trials,12–14 and it can be considered an option for ART sim-
plification in selected HIV-1-infected patients with sustained
viral suppression and no previous failures with PIs, as is
considered in some clinical guidelines.23
Since a higher CSF penetration and effectiveness score have
been associated with higher HIV suppression rates in CSF5–21
and better neurocognitive performance,6,7 there is some con-
cern about the capacity of PI/r monotherapy to effectively
suppress HIV replication in this anatomical compartment.20
Boosted lopinavir and darunavir both achieve CSF con-
centrations above the IC50 for the wild-type virus.
16,17 Viral
load rebound in CSF accompanied by mild or moderate
neurological symptoms, with or without viral suppression in
plasma, has been observed in some PI/r monotherapy clinical
trials,14–18 whereas others have reported no neurological
problems.12,13 In addition, more severe cases of encephalitis
associated with viral escape in CSF and plasma HIV-1 RNA
suppression have been described in patients receiving PI/r
monotherapy and also in patients receiving standard triple
ART.9,11 Recently, the prevalence of neurocognitive im-
pairment in virologically suppressed patients on PI/r mono-
therapy was evaluated in two observational studies, and PI/r
monotherapy was not associated with poorer neurocognitive
performance compared to triple therapy.24,25
In our case, the patient had a low nadir CD4 cell count and
previous treatment failure with nucleoside reverse tran-
scriptase inhibitors (NRTIs) and unboosted PIs; hence, al-
though plasma viral load remained below the limit of
detection and the patient was asymptomatic for a long time,
we must emphasize that PI/r monotherapy was not a good
simplification alternative according to current recommenda-
tions.15,23 The presence of the M184V mutation suggests
resistance selection while receiving lamivudine.
The patient had been treated for years with tenofovir, a drug
with poor CSF penetration,15 lamivudine, or emtricitabine, an
inactive drug (at least in the CSF) due to the M184Vmutation,
and lopinavir/ritonavir. We might speculate that she could
have received functional monotherapy without viral escape
during this period. However, tenofovir preserved at least some
degree of activity, and the presence of M184V could have an
additional effect on viral fitness.26 In addition, the selection
of PI resistance-associated mutations accompanying M184V
while receiving lamivudine and unboosted PIs cannot be
ruled out. In that case, the IC50 for lopinavir might be higher,
the genetic barrier of resistance lower, and simplification to
lopinavir/ritonavir could facilitate viral escape and accumu-
lation of PI resistance mutations in the CSF, whereas plasma
concentrations could suffice to maintain HIV-1 RNA under
the detection level.
In conclusion, although there is no strong published evi-
dence to date showing a higher risk of CSF viral escape and
neurological problems with boosted PI monotherapy com-
pared to standard combined ART, more studies are needed to
clarify this issue. If PI/r monotherapy is considered a sim-
plification strategy, rigorous patient selection is needed to
guarantee optimal viral suppression in the most difficult to
treat reservoirs, such as the CNS.
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